An Open-Label Phase I/IIa Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients
The purpose of this phase I/IIa study is to assess the safety and tolerability profile of TR399 in healthy volunteers and erectile dysfunction patients. This study will be conducted via a single-arm and open-label fashion.
100 Clinical Results associated with Tritech Biopharmaceuticals Co., Ltd.
0 Patents (Medical) associated with Tritech Biopharmaceuticals Co., Ltd.
100 Deals associated with Tritech Biopharmaceuticals Co., Ltd.
100 Translational Medicine associated with Tritech Biopharmaceuticals Co., Ltd.